About us
We’re in relentless pursuit of
breakthroughs that change patients’ lives.
Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development.
Our commitment
We are committed to providing shareholders, potential investors, and the public with a transparent view of our efforts toward fulfilling our purpose: Breakthroughs that change patients’ lives. To that end, our annual reports detail the strategic development, operations, and financial condition of our business.
We adhere to a strict vision & mission.
To bring life changing innovative medicines to patients in need and to add value for all stakeholders through actively exercising our beliefs of honesty, integrity and collaboration. We serve the needs of our patients and stakeholders to the best of our combined abilities.
What we're working on.
ATL1102
DMD is caused by a mutation in the muscle dystrophin gene leading to severe progressive muscle loss and premature death.
ATL1102
A disease in which the immune system eats away at the protective covering of nerves.
ATL1103
A disorder in adults in which the pituitary gland produces too much growth hormone.
Other indications
Limb-Girdle Muscular Dystrophy
A diseases that cause weakness and wasting of the muscles in the arms and legs.
Long Covid
A variety of new, returning or ongoing symptoms that people experience more than four weeks after getting COVID-19.
The people driving Antisense.
